![]() |
市場調查報告書
商品編碼
2133438
神經科器械市場規模、佔有率和趨勢分析 |全球| 2026–2032 | 包括神經調控器械、可移除線圈、液體栓塞劑及其他10個類別Neurological Device Market Size, Share and Trends Analysis | Global | 2026-2032 | Includes: Neuromodulation Devices, Detachable Coils, Liquid Embolics, and 10 more |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2025年,全球神經科設備市場規模為122億美元。預計該市場將以4.1%的複合年成長率成長,到2032年達到161億美元。
本報告涵蓋腦脊髓液管理裝置、可移除彈簧圈、液體栓塞劑、神經血管導管、神經血管導管導引線、神經血管支架、球囊閉塞裝置、動脈瘤夾、神經血管血栓管理裝置、神經調控裝置、鞘內幫浦、立體定位裝置和超音波吸引器。該報告對銷售量、手術量、平均售價、市場規模、成長率和企業市場占有率進行了定量分析,並包含截至2022年的歷史數據和截至2032年的預測數據。
全球人口老化導致水腦症和創傷性腦損傷等疾病的發生率上升,同時微創神經血管介入治療在血管內和介入治療領域的應用日益廣泛,這些因素共同塑造了這一市場格局。人工智慧、擴增實境和雲端神經影像平台等新興技術正在提升診斷準確性、術中導航水平和院際醫療協調能力,從而促進先進神經外科手術的更廣泛應用。
主要阻礙因素包括與腦脊髓液分流系統相關的併發症和再次手術負擔,以及與腦脊髓液管理領域產品創新進展緩慢的歷史。在該領域,醫院的預算限制和缺乏商業性獎勵,導致製造商的投資與醫療機構採用新設計之間形成負回饋循環。
市場概覽
全球神經科器械市場是醫療技術領域規模最大、種類最繁多的細分市場之一,涵蓋腦脊髓液管理、血管內神經介入、神經調控和神經外科器械。該市場既包括導管和導管導引線等高消耗品,也包括深部腦部刺激系統和鞘內泵等高價值的資本財和植入式平台。由於其涵蓋範圍廣泛,不同細分市場的成長要素和商業性趨勢差異顯著,人口趨勢、技術應用和報銷政策在不同適應症中發揮不同的作用。
新興技術正日益影響多個醫療設備領域的市場發展。人工智慧 (AI) 和機器學習透過先進的影像分析和預測建模,提高了診斷準確性和手術效率,從而能夠早期發現神經系統疾病並支援更個人化的治療方案。擴增實境(AR) 和虛擬實境 (VR) 透過提供患者解剖結構的即時3D視覺化影像,改進了神經外科培訓和術中導航。基於雲端的神經影像平台,尤其是在與人工智慧驅動的分析功能整合後,正在簡化資料管理,並實現遠距會診和協作醫療。
全球老化是影響多個醫療設備類別的重要人口因素。水腦症在老年族群中特別常見,隨著老年人口的成長,分流器和體外引流系統的需求也預計將增加。創傷性腦損傷病例的年發病率也在上升,這推動了神經血管和神經外科醫療設備手術數量的成長。此外,中風、顱內動脈瘤和運動障礙等可受益於神經調控療法的慢性神經系統疾病在老年人群中也更為常見,從而在多個細分市場中形成了持續的需求基礎。
微創神經血管手術市場持續成長,這主要得益於介入平台技術的進步和臨床證據的累積。血管內治療方法在動脈瘤治療、中風介入和栓塞術中逐漸取代傳統開放性手術,從而帶動了對可移除彈簧圈、液體栓塞劑、灌注支架、血栓摘取支架栓器和抽吸導管的需求。神經調控領域也透過脊髓刺激和深部腦部刺激平台不斷發展,這些平台如今能夠實現個人化治療方案的製定,並相容於磁振造影,擴大了其適用患者群體,並支持該領域的持續成長。
人口統計因素
水腦症在老年人群中比其他患者群體更為常見,隨著全球人口老化,預計該疾病的發生率將進一步上升。這推動了植入式和體外引流兩大類腦脊髓液引流產品及分流器需求的成長。人口結構的變化也促進了體外引流系統市場的擴張,因為越來越多的患者需要積極進行腦脊髓液管理。每年發生的創傷性腦損傷病例數量不斷增加,進一步推動了神經血管和神經外科器械手術數量的成長。這些人口老化和創傷趨勢在腦脊髓液管理、血栓管理、神經調控及相關領域創造了持續的需求基礎,支撐著市場成長,而這種成長在很大程度上獨立於手術技術的普及率。
技術進步
新型分流技術的出現使腦脊髓液(CSF)管理裝置成為醫生更具吸引力的治療選擇。同時,顱內壓監測技術的進步提高了水腦症的診斷率,並擴大了診斷族群。抗菌導管是腦脊髓液分流市場的另一個重大創新,其遠端塗覆抗菌塗層,旨在降低感染率和再次手術的負擔。這些進步有望提升腦脊髓液管理領域的平均售價(ASP),並推動市場價值成長。更廣泛地說,人工智慧影像分析、擴增實境(AR)手術導引和雲端神經影像技術的融合,正在提高多種適應症神經外科手術的準確性和效率,加速先進設備平台在市場上的應用。
分流術的有效性和再次手術的負擔。
水腦症術在正常運作的情況下療效顯著,但同時也可能引發多種併發症,並且經常需要再次手術。如果分流管發生阻塞、感染或移位,症狀可能會復發。這些症狀輕則表現為頭痛、噁心和嘔吐,重則表現為癲癇發作和認知併發症。大多數水腦症患者一生中至少需要一次再次手術,這不僅使患者面臨反覆手術的風險,也因併發症而非新的適應症而給醫療系統帶來持續的手術負擔。此外,分流管內含有磁性元件的患者必須嚴格遵守MRI掃描的安全指南,不僅使臨床管理更加複雜,也限制了診斷的柔軟性。
腦脊髓液(CSF)管理方面缺乏創新
醫療機構預算有限,當現有方案被認為臨床上足夠時,往往不願意採用更昂貴、更具創新性的產品。自1960年代首個腦水腦症器問世以來,其基本設計基本上保持不變,唯一顯著的改進是引入了可調節壓力閥。這形成了負回饋循環:當醫療機構的採購行為不重視獎勵,製造商就不太可能投資研發顯著改善的產品;而只要現有產品繼續有效,醫療服務提供者就沒有動力去倡導改變。政府主導的舉措,包括歐盟的政策外溢效應,有可能打破這種局面,刺激對腦脊髓液管理設計的新投資;然而,預計在短期預測期內,該領域真正意義上的創新仍將有限。
全球神經科設備市場概覽
競爭分析
新興市場與技術
市場趨勢
市場趨勢
涵蓋的治療
目標市場
目標區域
關鍵分析更新
報告的主要更新
版本歷史記錄
全球神經科設備市場概覽
The global neurological device market was valued at $12.2 billion in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 4.1%, reaching $16.1 billion by 2032.
This report covers cerebrospinal fluid (CSF) management devices, detachable coils, liquid embolics, neurovascular catheters, neurovascular guidewires, neurovascular stents, balloon occlusion devices, aneurysm clips, neurovascular thrombus management devices, neuromodulation devices, intrathecal pumps, stereotactic devices, and ultrasonic aspirators. It quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The market is shaped by an aging global population that is increasing the incidence of conditions such as hydrocephalus and traumatic brain injury, and by the growing adoption of minimally invasive neurovascular intervention across endovascular and interventional settings. Emerging technologies including artificial intelligence, augmented reality, and cloud-based neuroimaging platforms are improving diagnostic precision, intraoperative navigation, and cross-facility care coordination, supporting broader adoption of advanced neurological procedures.
Key restraints include complications and revision burdens associated with CSF shunt systems and a historically slow pace of product innovation in the CSF management segment, where hospital budget constraints and limited commercial incentive have maintained a negative feedback loop between manufacturer investment and institutional adoption of new designs.
Market Overview
The global neurological device market is one of the largest and most diverse segments in medical technology, spanning cerebrospinal fluid management, endovascular neurovascular intervention, neuromodulation, and neurosurgical instrumentation. The market encompasses both high-volume consumable categories such as catheters and guidewires and high-value capital and implantable platforms such as deep brain stimulation systems and intrathecal pumps. This breadth means that growth drivers and commercial dynamics vary meaningfully across segments, with demographic trends, technology adoption, and reimbursement policy each playing different roles depending on the indication.
Emerging technologies are increasingly shaping market development across multiple device categories. Artificial intelligence and machine learning are enhancing diagnostic precision and procedural efficiency through advanced imaging analysis and predictive modeling, enabling earlier detection of neurological conditions and supporting more personalized treatment pathways. Augmented and virtual reality are improving neurosurgical training and intraoperative navigation by providing real-time three-dimensional visualization of patient anatomy. Cloud-based neuroimaging platforms are streamlining data management and enabling remote consultation and coordinated care, particularly when integrated with AI-driven analytics.
An aging global population is the primary demographic driver across multiple device categories. Hydrocephalus affects the elderly disproportionately, and as this demographic grows, demand for shunts and external drainage systems will rise. The annual number of traumatic brain injury cases is also increasing, supporting procedural volume growth across neurovascular and neurosurgical device categories. Chronic neurological conditions such as stroke, intracranial aneurysm, and movement disorders that benefit from neuromodulation therapy are similarly more prevalent in older populations, creating a durable demand base across several market segments.
The market for minimally invasive neurovascular procedures continues to grow as interventional platforms become more capable and clinical evidence accumulates. Endovascular approaches to aneurysm treatment, stroke intervention, and embolization are displacing open surgical techniques, driving demand for detachable coils, liquid embolics, flow diversion stents, stent retrievers, and aspiration catheters. Neuromodulation is also expanding through spinal cord stimulation and deep brain stimulation platforms that now offer personalized therapy programming and MRI compatibility, broadening the eligible patient population and supporting sustained segment growth.
Market Drivers
Demographic Factors
Hydrocephalus affects the elderly more frequently than other patient groups, and as the global population ages the incidence of this condition will rise, driving increased demand for shunts and CSF drainage products across both implantable and external drainage categories. These demographic dynamics are also expanding the external drainage system market as more patients develop conditions requiring active cerebrospinal fluid management. The number of traumatic brain injury cases occurring annually is increasing, further contributing to procedural volume growth across neurovascular and neurosurgical device categories. This aging and injury trend creates a sustained demand base across CSF management, thrombus management, neuromodulation, and related segments, supporting market growth that is largely independent of procedural technology adoption rates.
Advancing Technology
Emerging shunt technologies are making CSF management devices a more attractive treatment option for physicians, while advances in intracranial pressure monitoring are improving hydrocephalus diagnosis rates and expanding the identified patient population. Antimicrobial catheters represent the next significant innovation in the CSF shunt market, with antimicrobial coatings on distal catheter ends designed to reduce infection rates and the associated revision burden. These advances are expected to support higher ASPs in the CSF management segment and drive market value growth. More broadly, the integration of AI-driven imaging analysis, AR-assisted surgical navigation, and cloud-based neuroimaging is improving the precision and efficiency of neurological procedures across multiple indications, accelerating adoption of advanced device platforms throughout the market.
Market Limiters
Shunt Efficacy and Revision Burden
Hydrocephalus shunts are effective when functioning correctly, but they are subject to multiple complications that frequently require revision surgery. Shunts can become blocked, infected, or disconnected, causing symptoms to re-emerge. These symptoms range from mild presentations such as headaches, nausea, and vomiting to more serious complications including seizures and cognitive dysfunction. Most patients with hydrocephalus will require at least one revision procedure during their lifetime, exposing them to repeated surgical risk and placing a sustained procedural burden on the healthcare system that reflects complications rather than new indications. Patients with magnetic components in their shunts must also follow highly specific safety guidelines for MRI procedures, adding clinical management complexity and limiting diagnostic flexibility.
Lack of Innovation in CSF Management
Healthcare centers operate with limited budgets and are often hesitant to adopt more expensive, innovative products when existing options are considered clinically adequate. Since the hydrocephalus shunt was first introduced in the 1960s, the core design has changed very little beyond the introduction of adjustable pressure valves. This creates a negative feedback loop in which manufacturers are unlikely to invest in significantly improved products when institutional purchasing behavior does not reward innovation, and providers see little incentive to advocate for change when current products remain functional. Government initiatives, including potential policy spillover effects from the European Union, have the potential to disrupt this dynamic and encourage renewed investment in CSF management design, but meaningful innovation in this segment remains limited over the near-term forecast period.
Market Coverage and Data Scope
Markets Covered and Segmentation
Competitive Analysis
Medtronic holds the leading position in the global neurological device market in 2025, supported by a broad and well-diversified portfolio across multiple segments. The company demonstrates particularly strong dominance in cerebrospinal fluid management, liquid embolics, intrathecal pumps, and stereotactic devices, while also maintaining a leading presence in neuromodulation and neurovascular stents. Medtronic also competes effectively in thrombus management and detachable coils, reinforcing its position across both therapeutic and interventional applications. This extensive segment coverage, combined with the ability to hold strong positions across several high-value device categories, enables Medtronic to sustain its global market leadership.
Stryker holds the second-leading position in 2025, driven by strength in neurovascular and stroke-related interventions. The company demonstrates leadership in neurovascular guidewires and ultrasonic aspiration while also maintaining a competitive position in detachable coils, balloon occlusion, neurovascular stents, and thrombus management. Stryker's portfolio is focused on interventional solutions, positioning it to capitalize on the growing demand for minimally invasive neurovascular procedures. This targeted strength across key endovascular segments supports its standing as a major global competitor.
Boston Scientific ranks as the third-leading competitor in 2025, with its position largely supported by strength in neuromodulation. The company has advanced beyond its earlier Precision systems and expanded its spinal cord stimulation portfolio with platforms such as WaveWriter Alpha and Spectra WaveWriter, which offer multi-waveform capabilities and enhanced programming for personalized therapy. Ongoing enhancements including MRI compatibility and integrated digital features strengthen its competitive position and allow it to maintain a leading standing in the overall market despite narrower segment diversification relative to the two market leaders.
Technology and Practice Trends
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
The Global Neurological Device Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, benchmark competitors, prioritize product development investments, and plan for growth across all major global regions.
Global Neurological Device Market Overview
Competitive Analysis
Emerging Markets And Technologies
Market Trends
Market Developments
Procedures Included
Markets Included
Regions Included
Key Analysis Updates
Key Report Updates
Version History
Global Neurological Device Market Overview